📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare Limited has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a veteran of the TTK Group, having served nearly three decades with the group and retiring as the CFO of TTK Prestige Ltd in 2020. The appointment is subject to shareholder approval through a postal ballot process, with voting concluding on January 24, 2026. This appointment is expected to strengthen the company's financial governance and audit frameworks given his 40 years of experience in finance and regulatory compliance.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting December 22, 2025.
The appointee brings nearly 40 years of experience and previously served as the CFO of TTK Prestige Ltd.
Shareholder approval will be sought via postal ballot with the final results to be declared by January 28, 2026.
Mr. Sundaresan is a Fellow Member of the Institute of Chartered Accountants of India (FCA) with expertise in ERP implementation and corporate restructuring.
👀 What to Watch
Investors should view this as a positive governance move that brings deep institutional knowledge and financial expertise to the board. No immediate action is required as this is a routine high-level management appointment.
